Metsunix

Active Ingredient:: Metformin Hydrochloride, Sitagliptin
Origin:: EU

Metsunix (Metformin Hydrochloride, Sitagliptin)

Q: What is Metsunix used for?

Metsunix is a prescription oral medication that combines metformin and sitagliptin to improve blood‑sugar control in adults with type 2 diabetes mellitus, typically used when diet, exercise, and metformin alone are insufficient.

Q: How does Metformin and Sitagliptin work?

Metformin lowers hepatic glucose production and increases peripheral insulin sensitivity, while sitagliptin blocks the DPP‑4 enzyme, prolonging the action of incretin hormones that stimulate insulin release and suppress glucagon, together providing complementary glucose‑lowering effects.

Q: What is the usual dose of Metsunix?

The dose of Metsunix is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength and dosing schedule.

Q: Is Metsunix safe in pregnancy or breastfeeding?

Safety of Metsunix during pregnancy or lactation has not been established. It should be used only if the potential benefit justifies the possible risk to the fetus or infant, and under close medical supervision.

Q: How do I order Metsunix from GNH India?

To order Metsunix, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Q: How does Metsunix compare with separate metformin and sitagliptin tablets?

Metsunix delivers a fixed‑dose combination, simplifying the regimen by reducing pill burden and improving adherence compared with taking metformin and sitagliptin as separate tablets, while providing the same pharmacological benefits of each component.

Q: What are the storage and handling requirements for Metsunix?

Metsunix tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and heat. Keep the container tightly closed and out of direct sunlight.

Q: How is Metsunix administered?

Metsunix is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing relative to meals.

Q: What are the most serious risks associated with Metsunix?

The most serious risks include lactic acidosis (a rare but life‑threatening condition linked to metformin), pancreatitis, severe hypoglycaemia when combined with insulin or sulfonylureas, and rare allergic reactions such as anaphylaxis.

Q: Who should not use Metsunix?

Metsunix is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, or in those with a history of lactic acidosis. Caution is also advised for patients with significant hepatic disease.

Metformin Hydrochloride and Sitagliptin, the active ingredients in Metsunix, constitute a fixed‑dose combination of a biguanide and a DPP‑4 inhibitor presented as an oral tablet for the management of type 2 diabetes mellitus in adult patients. The formulation leverages metformin’s ability to lower hepatic glucose output together with sitagliptin’s enhancement of incretin activity to improve overall glycaemic control.

GNH India supplies Metsunix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality through stringent manufacturing standards and provides regulatory documentation for global distribution.

Manufacturer / TM Owner

Adamed S.R.L.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Metsunix is indicated for the treatment of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance and impaired glucose regulation.

Type 2 diabetes mellitus: improves glycaemic control when used with diet and exercise.
Adjunct to metformin monotherapy: provides additional HbA1c reduction in patients inadequately controlled on metformin alone.
Combination therapy with insulin: helps lower insulin dose requirements while maintaining target glucose levels.

How It Works

Metformin acts primarily by inhibiting hepatic gluconeogenesis and enhancing peripheral insulin sensitivity, thereby reducing fasting glucose production. Sitagliptin selectively blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which prolongs the activity of endogenous incretin hormones (GLP‑1 and GIP). The increased incretin effect stimulates glucose‑dependent insulin secretion and suppresses glucagon release, complementing metformin’s actions to achieve better overall glycaemic control.

Side Effects

Metsunix may be associated with a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects

Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
Headache: mild to moderate intensity.
Upper respiratory tract infection: nasopharyngitis or cough.
Hypoglycaemia (when combined with insulin or sulfonylureas): symptomatic low blood glucose.

Serious or Rare Side Effects

Lactic acidosis: rare but potentially fatal metabolic complication.
Pancreatitis: severe abdominal pain with elevated enzymes.
Severe allergic reactions: rash, angioedema, or anaphylaxis.
Hepatic dysfunction: marked elevation of liver enzymes or hepatitis.

Precautions & Warnings

Before prescribing Metsunix, clinicians should consider several precautionary measures to minimise risk.

Renal function assessment: avoid use in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) due to lactic acidosis risk.
Hepatic disease monitoring: use cautiously in patients with liver dysfunction as metformin clearance may be reduced.
Risk of hypoglycaemia: adjust dose of concomitant insulin or sulfonylureas to prevent low blood glucose episodes.
Contraindication with iodinated contrast: discontinue metformin before and after contrast procedures to reduce lactic acidosis risk.
Pregnancy and lactation: safety not established; prescribe only if potential benefit outweighs risk.
Store at ambient temperature: keep in original container, protect from moisture and heat.

Avoid Interactions

Metsunix can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

Insulin or sulfonylureas: increased risk of severe hypoglycaemia.
Iodinated contrast agents: may precipitate metformin‑associated lactic acidosis; discontinue metformin before imaging.
Cimetidine: can raise sitagliptin plasma concentrations, increasing adverse effect risk.

Moderate Interactions (Monitor Closely)

Diuretics (especially thiazides): may affect renal function and metformin clearance.
ACE inhibitors or ARBs: monitor renal function and electrolytes when combined.
Beta‑blockers: may mask hypoglycaemia symptoms, requiring closer glucose monitoring.

Frequently Asked Questions

Metsunix is a prescription oral medication that combines metformin and sitagliptin to improve blood‑sugar control in adults with type 2 diabetes mellitus, typically used when diet, exercise, and metformin alone are insufficient.

Metformin lowers hepatic glucose production and increases peripheral insulin sensitivity, while sitagliptin blocks the DPP‑4 enzyme, prolonging the action of incretin hormones that stimulate insulin release and suppress glucagon, together providing complementary glucose‑lowering effects.

The dose of Metsunix is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength and dosing schedule.

Safety of Metsunix during pregnancy or lactation has not been established. It should be used only if the potential benefit justifies the possible risk to the fetus or infant, and under close medical supervision.

To order Metsunix, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Metsunix delivers a fixed‑dose combination, simplifying the regimen by reducing pill burden and improving adherence compared with taking metformin and sitagliptin as separate tablets, while providing the same pharmacological benefits of each component.

Metsunix tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and heat. Keep the container tightly closed and out of direct sunlight.

Metsunix is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing relative to meals.

The most serious risks include lactic acidosis (a rare but life‑threatening condition linked to metformin), pancreatitis, severe hypoglycaemia when combined with insulin or sulfonylureas, and rare allergic reactions such as anaphylaxis.

Metsunix is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, or in those with a history of lactic acidosis. Caution is also advised for patients with significant hepatic disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 08 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.